Judith Anne Shizuru - 22 Sep 2025 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Reporting relationship: Director
Issuer ticker: JSPR
Reported as of: 22 Sep 2025
Net transaction value: +$99,630
SEC form: 4
Accepted by SEC: 24 Sep 2025, 16:01:03 UTC
Prior SEC filing: 03 Jul 2025
Next SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Herb Cross, as Attorney-in-Fact

Key filing fact

Judith Anne Shizuru filed Form 4 for Jasper Therapeutics, Inc. (JSPR) on 24 Sep 2025.

Key facts

This page summarizes Judith Anne Shizuru's Form 4 filing for Jasper Therapeutics, Inc. (JSPR).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Sep 2025, 16:01.

Change

Previous filing in this sequence was filed on 03 Jul 2025.
Current net transaction value: +$99,630.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001883000 Primary reporting owner

Shizuru Judith Anne

Relationship: Director
Address: C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PKWY, SUITE #102, REDWOOD CITY
Signature: /s/ Herb Cross, as Attorney-in-Fact
Signature date: 24 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JSPR transaction

Voting Common Stock

Purchase

Transaction value: $99,630
Shares: +41,000
Change %: +35%
Price: $2.43
Shares after: 156,901
Date: 22 Sep 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JSPR transaction Derivative

Common Stock Warrant (right to buy)

Purchase

Transaction value
Shares: +41,000
Change %
Price
Shares after: 41,000
Date: 22 Sep 2025
Ownership: Direct
Underlying class: Voting Common Stock
Underlying amount: 41,000
Exercise price: $2.92
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant.